Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033317 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
A Phase 2 study, sponsored by Relypsa.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02033317: Clinical Trial Phase 2 study, sponsored by Relypsa.
NCT02033317 is a Phase 2 study that was terminated before completion, run by Relypsa. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02033317, a Phase 2 study, was terminated before completion, sponsored by Relypsa.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
Interventions
- DRUG patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Why NCT02033317 stopped before completion
NCT02033317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which patiromer is the first listed.
NCT02033317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02033317 about?
NCT02033317 is a clinical study titled "An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis". This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
What is the current status of trial NCT02033317?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT02033317?
The interventions under investigation include: patiromer (DRUG).
Who is sponsoring clinical trial NCT02033317?
This trial is sponsored by Relypsa, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02033317's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia